Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2014 Jul 10;31:S113–S114. doi: 10.1016/j.nbt.2014.05.1888

In vitro assay by bioengineering of new antiviral drugs

Viktor Tashuta 1,, Zinaida Klestova 2, Alla Voronina 3, Shota Dgebuadze 4
PMCID: PMC8485177

The viral diseases are still increasing. There is a wide spectrum of tested antiviral compounds, application of which inhibits or stops viral activity, but universal antiviral means are absent.

The investigation was aimed to finding the new approaches of the infection eradication.

Methods: test-model viruses–members of Herpesviridae and Coronaviridae family; continuous animal cell cultures:–cell culture of versenised swine embryonic kidney (CCVSEK), BHK-21, Vero, SK-6. For investigation of anti-virus properties we have applied a complex of standard methods.

Results of experimental research of cytotoxic and antiviral actions of 10 new substances from indol derivates are presented. We show the data about all examined means that significantly reduced the infection activity of tested virus strains in vitro systems in different ways. We tested different schemes of antivirus actions of tested substances in creation of treatment by viral infection process, as preventive as treatment. But the highest antiviral activity among tested substances was shown by decreased viral infection activity to 7,04 ± 0,04 lg ТCID50/ml.

Conclusion: All tested means are suitable in using for clinical research for testing in eradication virus infections. The results confirm the perspective of tested means for production of new antiviral drugs.

The results were obtained through STCU grant # p450 by financial support of KCP.


Articles from New Biotechnology are provided here courtesy of Elsevier

RESOURCES